Latest stories on ANIK
Q3 2026 Anika Therapeutics Inc Earnings Call Transcript
GuruFocus50 · neutralearnings
Anika projects 6%-10% 2026 revenue growth while targeting 15%-17% adjusted EBITDA margin
Seeking Alpha63 · neutralearnings
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Anika Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Anika Therapeutics (ANIK) Q3 2026 Earnings Call Transcript
The Motley Fool74 · bullishearnings
Anika Therapeutics narrows FY26 revenue view to up 6%-10% from up 5%-10%
The Fly58 · neutralearnings
Anika Therapeutics reports Q3 adjusted EPS 29c, consensus 17c
The Fly67 · bullishearnings
Anika Therapeutics backs FY27 revenue view flat to up 5%
The Fly52 · neutralearnings
Anika Therapeutics, Inc. (ANIK) files 8-K
SEC 8-K50 · neutralgeneral
Anika Therapeutics GAAP EPS of -$0.02 misses by $0.08, revenue of $30.59M beats by $1.15M
Seeking Alpha48 · neutralearnings
Anika Reports Third Quarter 2026 Financial Results
GlobeNewswire61 · neutralearnings
Anika Reports Third Quarter 2026 Financial Results
Business Insider61 · neutralearnings
Anika Therapeutics Q3 2026 Earnings Preview
Seeking Alpha50 · neutralearnings
ANI Pharmaceuticals raises FY26 adjusted EPS to $9.37-$9.71 from $9.19-$9.69
The Fly63 · neutralearnings
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
GlobeNewswire50 · neutralgeneral
ANI Pharma reports positive phase 4 data for Iluvien in non-infectious uveitis
Seeking Alpha74 · bullishproduct/pr
B.Riley assumes Anika Therapeutics stock coverage with buy rating
Investing.com Analyst Ratings61 · neutralanalyst
Anika Therapeutics assumed with a Buy at B. Riley
The Fly61 · neutralanalyst
Anika (ANIK) Q2 2026 Earnings Call Transcript
The Motley Fool68 · bullishearnings
Anika Therapeutics Lifts Outlook After Margin Surge
TipRanks73 · bullishearnings
These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months
Stocktwits News68 · bullishearnings
Anika projects 2026 adjusted EBITDA margin of 13% to 17% as it raises revenue growth outlook to 5% to 10%
Seeking Alpha67 · bullishearnings
Anika Therapeutics, Inc. (ANIK) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Anika Therapeutics, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance50 · neutralearnings